The BioAge platform identifies key molecular mechanisms of healthy human longevity and reveals new drug targets for diseases of aging
Our platform
65M+ data points across 10K+ patients over 45+ years of human aging
Analyze longitudinal samples connected to health records, representing decades of human aging
Measure 10K+ molecules per sample using cutting-edge multi-omics
Leverage AI to map longevity pathways and identify drug targets
Validate targets & assets in naturally aged animal models
Develop novel molecules through in-licensing or internal discovery
Perform efficient trials in acute diseases
Unprecedented visibility into human aging
BioAge’s diverse human aging cohorts contain patients’ longitudinal samples, data, and health records for up to 45 years.
Why we start with human data
translational aspects of known aging biology
predictive aging biomarkers
highly novel biology of human aging
Our cohorts
begin with healthy middle-aged patients, allowing us to track aging outcomes and identify what drives them
Why we use longitudinal data
Our data first, mechanism-agnostic approach
Mechanism-agnostic approach enables us to identify drugs targets at the intersection of known and novel aging biology
From human discovery in silico to focused mechanistic validation in vivo
Targets and assets revealed by our discovery platform are rigorously validated in naturally aged rodent models of disease. To ensure human relevance, we focus on aspects of aging that unfold in similar ways in mice and humans.
